Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity.

J Exp Med
Authors
Abstract

Th17 cells are key players in defense against pathogens and maintaining tissue homeostasis, but also act as critical drivers of autoimmune diseases. Based on single-cell RNA-seq profiling of pathogenic versus nonpathogenic Th17 cells, we identified protein C receptor (PROCR) as a cell surface molecule expressed in covariance with the regulatory module of Th17 cells. Although PROCR expression in T cells was controlled by the cooperative action of the Th17 lineage-specific transcription factors RORγt, IRF4, and STAT3, PROCR negatively regulated Th17 differentiation. CD4(+) T cells from PROCR low expressor mutant mice readily differentiated into Th17 cells, whereas addition of the PROCR ligand, activated protein C, inhibited Th17 differentiation in vitro. In addition, PROCR acted as a negative regulator of Th17 pathogenicity in that it down-regulated expression of several pathogenic signature genes, including IL-1 and IL-23 receptors. Furthermore, T cell-specific deficiency of PROCR resulted in the exacerbation of experimental autoimmune encephalomyelitis (EAE) and higher frequencies of Th17 cell in vivo, indicating that PROCR also inhibits pathogenicity of Th17 cells in vivo. PROCR thus does not globally inhibit Th17 responses but could be targeted to selectively inhibit proinflammatory Th17 cells.

Year of Publication
2016
Journal
J Exp Med
Volume
213
Issue
11
Pages
2489-2501
Date Published
2016 Oct 17
ISSN
1540-9538
DOI
10.1084/jem.20151118
PubMed ID
27670590
PubMed Central ID
PMC5068226
Links
Grant list
R01 NS030843 / NS / NINDS NIH HHS / United States
R00 AI110649 / AI / NIAID NIH HHS / United States
P01 AI056299 / AI / NIAID NIH HHS / United States
K01 DK090105 / DK / NIDDK NIH HHS / United States
K22 AI093671 / AI / NIAID NIH HHS / United States
P01 AI073748 / AI / NIAID NIH HHS / United States